EP4347571B1 - Triazine derivatives and their use in the treatment of cancer. - Google Patents
Triazine derivatives and their use in the treatment of cancer.Info
- Publication number
- EP4347571B1 EP4347571B1 EP22731614.8A EP22731614A EP4347571B1 EP 4347571 B1 EP4347571 B1 EP 4347571B1 EP 22731614 A EP22731614 A EP 22731614A EP 4347571 B1 EP4347571 B1 EP 4347571B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- methyl
- mmol
- triazin
- amino
- piperidyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MA64830A MA64830B1 (fr) | 2021-06-04 | 2022-06-02 | Dérivés de triazine et leur utilisation pour la traitement de cancer. |
| RS20260704A RS68198B1 (sr) | 2021-06-04 | 2022-06-02 | Derivati triazina i njihova upotreba u lečenju karcinoma |
| HRP20260777TT HRP20260777T1 (hr) | 2021-06-04 | 2022-06-02 | Derivati triazina i njihova primjena u liječenju raka |
| SM20260264T SMT202600264T1 (it) | 2021-06-04 | 2022-06-02 | Derivati della triazina e loro uso nel trattamento del cancro |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21177660 | 2021-06-04 | ||
| EP21188639 | 2021-07-30 | ||
| EP21215875 | 2021-12-20 | ||
| PCT/EP2022/064995 WO2022253936A1 (en) | 2021-06-04 | 2022-06-02 | Triazine derivatives and their use in the treatment of cancer. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4347571A1 EP4347571A1 (en) | 2024-04-10 |
| EP4347571B1 true EP4347571B1 (en) | 2026-04-22 |
Family
ID=82115763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP22731614.8A Active EP4347571B1 (en) | 2021-06-04 | 2022-06-02 | Triazine derivatives and their use in the treatment of cancer. |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20240132471A1 (enExample) |
| EP (1) | EP4347571B1 (enExample) |
| JP (2) | JP7705963B2 (enExample) |
| KR (1) | KR20240019083A (enExample) |
| AR (1) | AR126053A1 (enExample) |
| AU (1) | AU2022287224A1 (enExample) |
| BR (1) | BR112023025318A2 (enExample) |
| CA (1) | CA3216026A1 (enExample) |
| CL (1) | CL2023003491A1 (enExample) |
| CO (1) | CO2023016212A2 (enExample) |
| CR (1) | CR20230566A (enExample) |
| DK (1) | DK4347571T3 (enExample) |
| ES (1) | ES3072832T3 (enExample) |
| FI (1) | FI4347571T3 (enExample) |
| HR (1) | HRP20260777T1 (enExample) |
| IL (1) | IL307201A (enExample) |
| LT (1) | LT4347571T (enExample) |
| MA (1) | MA64830B1 (enExample) |
| MX (1) | MX2023013998A (enExample) |
| PE (1) | PE20240928A1 (enExample) |
| RS (1) | RS68198B1 (enExample) |
| SM (1) | SMT202600264T1 (enExample) |
| WO (1) | WO2022253936A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| WO2022230912A1 (ja) | 2021-04-28 | 2022-11-03 | アステラス製薬株式会社 | 置換トリアジン化合物 |
| EP4347571B1 (en) * | 2021-06-04 | 2026-04-22 | F. Hoffmann-La Roche AG | Triazine derivatives and their use in the treatment of cancer. |
| MX2024008548A (es) * | 2022-01-07 | 2024-07-19 | Transthera Sciences Nanjing Inc | Inhibidor del inflamosoma nlrp3 y uso del mismo. |
| JP2025523930A (ja) * | 2022-07-21 | 2025-07-25 | エフ． ホフマン－ラ ロシュ アーゲー | Ｎｌｒｐ３阻害剤 |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| US20260167637A1 (en) * | 2022-11-04 | 2026-06-18 | Transthera Sciences (Nanjing), Inc. | Nlrp3 inflammasome inhibitor and use thereof |
| JP2025540202A (ja) * | 2022-12-07 | 2025-12-11 | エフ． ホフマン－ラ ロシュ アーゲー | Ｎｌｒｐ３阻害のモジュレーターとしての新規化合物 |
| EP4683918A1 (en) * | 2023-03-20 | 2026-01-28 | Insilico Medicine IP Limited | Nlrp3 inflammasome inhibitors and uses thereof |
| JP2026509587A (ja) * | 2023-03-23 | 2026-03-19 | 成都▲ざ▼▲霊▼生物医▲薬▼科技有限公司 | トリアジン化合物およびその使用 |
| CN120958000A (zh) * | 2023-04-19 | 2025-11-14 | 豪夫迈·罗氏有限公司 | 噁唑并[4,5-b]吡嗪和噁唑并[4,5-b]吡啶衍生物作为nlrp3抑制剂用于治疗例如炎症性疾病 |
| JP2026514799A (ja) * | 2023-04-19 | 2026-05-13 | エフ． ホフマン－ラ ロシュ アーゲー | 炎症性疾患の処置のためのｎｌｐｒ３阻害剤としての５－［５－（２－ヒドロキシフェニル）オキサゾロ［４，５－ｂ］ピリジン－２－イル］ピペリジン－２－オン誘導体 |
| AU2024280075A1 (en) | 2023-06-02 | 2025-12-11 | Merck Sharp & Dohme Llc | 5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3 |
| CN121586712A (zh) * | 2023-07-28 | 2026-02-27 | 豪夫迈·罗氏有限公司 | 新颖化合物 |
| WO2025046419A1 (ko) * | 2023-08-25 | 2025-03-06 | 제일약품주식회사 | Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| TW202545527A (zh) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法 |
| WO2025252772A1 (en) * | 2024-06-06 | 2025-12-11 | F. Hoffmann-La Roche Ag | Triazine derivatives |
| WO2026046981A1 (en) | 2024-08-28 | 2026-03-05 | F. Hoffmann-La Roche Ag | Solid forms of 5-[3-[[(3r)-1-ethyl-3-piperidyl]amino]-5-methyl-1,2,4-triazin-6-yl]-2,3- dihydrobenzofuran-4-ol |
| WO2026067453A1 (en) * | 2024-09-25 | 2026-04-02 | Insilico Medicine Ip Limited | Novel compounds as nlrp3 inflammasome inhibitors and uses thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020001425A (es) * | 2017-08-04 | 2020-08-06 | Skyhawk Therapeutics Inc | Metodos y composiciones para modular el empalme. |
| MX2020001776A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| CN111315733A (zh) | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
| BR112020019373A2 (pt) * | 2018-03-27 | 2020-12-29 | Ptc Therapeutics, Inc. | Compostos para o tratamento da doença de hutington |
| US12168012B2 (en) | 2018-07-25 | 2024-12-17 | Novartis Ag | NLRP3 inflammasome inhibitors |
| WO2020163248A1 (en) * | 2019-02-04 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| BR112022014480A2 (pt) | 2020-01-22 | 2022-09-13 | Hoffmann La Roche | Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit |
| CN115279739B (zh) | 2020-03-27 | 2025-07-22 | 尼科治疗有限公司 | 取代哒嗪化合物 |
| TW202231281A (zh) | 2020-12-25 | 2022-08-16 | 大陸商上海拓界生物醫藥科技有限公司 | 一類含噠嗪的化合物及其醫藥用途 |
| EP4289823A4 (en) | 2021-02-08 | 2025-02-26 | Medshine Discovery Inc. | SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| WO2022230912A1 (ja) | 2021-04-28 | 2022-11-03 | アステラス製薬株式会社 | 置換トリアジン化合物 |
| EP4347571B1 (en) * | 2021-06-04 | 2026-04-22 | F. Hoffmann-La Roche AG | Triazine derivatives and their use in the treatment of cancer. |
| CN115433163A (zh) | 2021-06-05 | 2022-12-06 | 药捷安康(南京)科技股份有限公司 | Nlrp3炎症小体抑制剂及其应用 |
| PL4363406T3 (pl) | 2021-07-02 | 2026-01-05 | Astrazeneca Ab | Inhibitory inflamasomu nlrp3 |
| WO2023028536A1 (en) | 2021-08-25 | 2023-03-02 | Ptc Therapeutics, Inc. | 1,2,4-triazine derivatives useful as inhibitors of nlrp3 |
| WO2023066377A1 (zh) | 2021-10-22 | 2023-04-27 | 索智生物科技（浙江）有限公司 | 一种含氮化合物、其制备方法及应用 |
| MX2024008548A (es) | 2022-01-07 | 2024-07-19 | Transthera Sciences Nanjing Inc | Inhibidor del inflamosoma nlrp3 y uso del mismo. |
| KR20250005125A (ko) | 2022-03-25 | 2025-01-09 | 벤투스 테라퓨틱스 유에스 인코포레이티드 | NLRP3 유도체로서 유용한 피리도-[3,4-d]피리다진 아민 유도체 |
| CN120152974A (zh) | 2022-10-26 | 2025-06-13 | 天维生物制药有限公司 | 缩环哒嗪衍生物 |
| CN115621720B (zh) * | 2022-10-27 | 2026-07-07 | 永道射频技术股份有限公司 | 一种应用于rfid读写器的全息超材料阵列天线 |
| US20260167637A1 (en) | 2022-11-04 | 2026-06-18 | Transthera Sciences (Nanjing), Inc. | Nlrp3 inflammasome inhibitor and use thereof |
| US20260200914A1 (en) | 2022-12-28 | 2026-07-16 | Astrazeneca Ab | Nlrp3 inflammasome inhibitors |
| WO2024169858A1 (zh) | 2023-02-17 | 2024-08-22 | 成都赜灵生物医药科技有限公司 | 六元氮杂环类化合物及其用途 |
-
2022
- 2022-06-02 EP EP22731614.8A patent/EP4347571B1/en active Active
- 2022-06-02 RS RS20260704A patent/RS68198B1/sr unknown
- 2022-06-02 HR HRP20260777TT patent/HRP20260777T1/hr unknown
- 2022-06-02 MA MA64830A patent/MA64830B1/fr unknown
- 2022-06-02 FI FIEP22731614.8T patent/FI4347571T3/fi active
- 2022-06-02 JP JP2023572751A patent/JP7705963B2/ja active Active
- 2022-06-02 LT LTEPPCT/EP2022/064995T patent/LT4347571T/lt unknown
- 2022-06-02 CR CR20230566A patent/CR20230566A/es unknown
- 2022-06-02 BR BR112023025318A patent/BR112023025318A2/pt unknown
- 2022-06-02 AR ARP220101456A patent/AR126053A1/es unknown
- 2022-06-02 CA CA3216026A patent/CA3216026A1/en active Pending
- 2022-06-02 MX MX2023013998A patent/MX2023013998A/es unknown
- 2022-06-02 KR KR1020237039328A patent/KR20240019083A/ko active Pending
- 2022-06-02 DK DK22731614.8T patent/DK4347571T3/da active
- 2022-06-02 WO PCT/EP2022/064995 patent/WO2022253936A1/en not_active Ceased
- 2022-06-02 IL IL307201A patent/IL307201A/en unknown
- 2022-06-02 ES ES22731614T patent/ES3072832T3/es active Active
- 2022-06-02 PE PE2023003133A patent/PE20240928A1/es unknown
- 2022-06-02 SM SM20260264T patent/SMT202600264T1/it unknown
- 2022-06-02 AU AU2022287224A patent/AU2022287224A1/en active Pending
-
2023
- 2023-11-23 CL CL2023003491A patent/CL2023003491A1/es unknown
- 2023-11-29 CO CONC2023/0016212A patent/CO2023016212A2/es unknown
- 2023-11-30 US US18/524,678 patent/US20240132471A1/en not_active Abandoned
-
2025
- 2025-02-25 US US19/063,141 patent/US12421209B2/en active Active
- 2025-03-26 JP JP2025051003A patent/JP2025098157A/ja active Pending
- 2025-05-16 US US19/210,925 patent/US20250276958A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022287224A1 (en) | 2023-09-21 |
| CL2023003491A1 (es) | 2024-05-24 |
| EP4347571A1 (en) | 2024-04-10 |
| CA3216026A1 (en) | 2022-12-08 |
| AR126053A1 (es) | 2023-09-06 |
| MA64830B1 (fr) | 2026-06-30 |
| US12421209B2 (en) | 2025-09-23 |
| WO2022253936A1 (en) | 2022-12-08 |
| CO2023016212A2 (es) | 2023-12-11 |
| CR20230566A (es) | 2024-01-22 |
| RS68198B1 (sr) | 2026-06-30 |
| BR112023025318A2 (pt) | 2024-02-27 |
| HRP20260777T1 (hr) | 2026-08-14 |
| TW202313577A (zh) | 2023-04-01 |
| JP2024522494A (ja) | 2024-06-21 |
| US20240132471A1 (en) | 2024-04-25 |
| MX2023013998A (es) | 2023-12-11 |
| SMT202600264T1 (it) | 2026-07-16 |
| KR20240019083A (ko) | 2024-02-14 |
| JP2025098157A (ja) | 2025-07-01 |
| FI4347571T3 (fi) | 2026-06-17 |
| US20250276958A1 (en) | 2025-09-04 |
| DK4347571T3 (da) | 2026-06-29 |
| ES3072832T3 (en) | 2026-07-06 |
| US20250197370A1 (en) | 2025-06-19 |
| LT4347571T (lt) | 2026-07-10 |
| IL307201A (en) | 2023-11-01 |
| JP7705963B2 (ja) | 2025-07-10 |
| PE20240928A1 (es) | 2024-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12421209B2 (en) | Compounds | |
| EP4337652B1 (en) | Nlrp3 inhibitors | |
| US20240409553A1 (en) | Heterocyclic nlrp3 inhibitors | |
| US20250353830A1 (en) | Novel compounds | |
| TW202434581A (zh) | 新穎化合物 | |
| TW202428282A (zh) | 新穎化合物 | |
| US20260015353A1 (en) | Novel compounds | |
| TW202428281A (zh) | 新穎化合物 | |
| CN117460718A (zh) | 三嗪衍生物及其在癌症的治疗中的用途 | |
| RU2861618C2 (ru) | Триазиновые производные и их применение в лечении рака | |
| EA052779B1 (ru) | Триазиновые производные и их применение в лечении рака | |
| HK40101872A (en) | Triazine derivatives and their use in the treatment of cancer | |
| HK40111084A (en) | Heterocyclic nlrp3 inhibitors | |
| EP4698537A1 (en) | 5-[5-(2-hydroxyphenyl)oxazolo[4,5-b]pyridin-2-yl]piperidin-2-one derivatives as nlpr3 inhibitors for the treatment of inflammatory diseases | |
| CN121586712A (zh) | 新颖化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REG | Reference to a national code |
Ref country code: HR Ref legal event code: TUEP Ref document number: P20260777T Country of ref document: HR |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20240104 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAX | Request for extension of the european patent (deleted) | ||
| RAV | Requested validation state of the european patent: fee paid |
Extension state: MA Effective date: 20240104 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20250513 |
|
| GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| INTC | Intention to grant announced (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20250730 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20251203 |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Free format text: CASE NUMBER: UPC_APP_0017471_4347571/2025 Effective date: 20251212 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: F10 Free format text: ST27 STATUS EVENT CODE: U-0-0-F10-F00 (AS PROVIDED BY THE NATIONAL OFFICE) Effective date: 20260422 Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602022035025 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20260520 Year of fee payment: 5 Ref country code: LU Payment date: 20260520 Year of fee payment: 5 |
|
| REG | Reference to a national code |
Ref country code: FI Ref legal event code: FGE Ref country code: PT Ref legal event code: SC4A Ref document number: 4347571 Country of ref document: PT Date of ref document: 20260617 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20260611 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: W10 Free format text: ST27 STATUS EVENT CODE: U-0-0-W10-W00 (AS PROVIDED BY THE NATIONAL OFFICE) Effective date: 20260624 |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20260624 |
|
| REG | Reference to a national code |
Ref country code: MA Ref legal event code: VAGR Ref document number: 64830 Country of ref document: MA Kind code of ref document: B1 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: U11 Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE) Effective date: 20260701 Ref country code: NL Ref legal event code: FP |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SM Payment date: 20260619 Year of fee payment: 5 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 3072832 Country of ref document: ES Kind code of ref document: T3 Effective date: 20260706 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20260520 Year of fee payment: 5 Ref country code: RS Payment date: 20260526 Year of fee payment: 5 Ref country code: DK Payment date: 20260624 Year of fee payment: 5 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20260623 Year of fee payment: 5 Ref country code: GR Payment date: 20260626 Year of fee payment: 5 Ref country code: MC Payment date: 20260528 Year of fee payment: 5 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20260520 Year of fee payment: 5 Ref country code: LT Payment date: 20260520 Year of fee payment: 5 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FI Payment date: 20260520 Year of fee payment: 5 Ref country code: AT Payment date: 20260714 Year of fee payment: 5 Ref country code: SE Payment date: 20260520 Year of fee payment: 5 |
|
| REG | Reference to a national code |
Ref country code: EE Ref legal event code: FG4A Ref document number: E025868 Country of ref document: EE Effective date: 20260605 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: HU Payment date: 20260611 Year of fee payment: 5 Ref country code: RO Payment date: 20260602 Year of fee payment: 5 Ref country code: BE Payment date: 20260520 Year of fee payment: 5 Ref country code: IE Payment date: 20260522 Year of fee payment: 5 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: EE Payment date: 20260630 Year of fee payment: 5 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IS Payment date: 20260609 Year of fee payment: 5 Ref country code: PT Payment date: 20260626 Year of fee payment: 5 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CZ Payment date: 20260528 Year of fee payment: 5 Ref country code: TR Payment date: 20260525 Year of fee payment: 5 |
|
| RAP4 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: F. HOFFMANN-LA ROCHE AG |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20260520 Year of fee payment: 5 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LV Payment date: 20260612 Year of fee payment: 5 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BG Payment date: 20260527 Year of fee payment: 5 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MT Payment date: 20260528 Year of fee payment: 5 |
|
| REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20260777T Country of ref document: HR Payment date: 20260615 Year of fee payment: 5 |
|
| REG | Reference to a national code |
Ref country code: SK Ref legal event code: T3 Ref document number: E 48743 Country of ref document: SK |